Literature DB >> 22789042

Human rights responsibilities of pharmaceutical companies in relation to access to medicines.

Joo-Young Lee1, Paul Hunt.   

Abstract

Although access to medicines is a vital feature of the right to the highest attainable standard of health ("right to health"), almost two billion people lack access to essential medicines, leading to immense avoidable suffering. While the human rights responsibility to provide access to medicines lies mainly with States, pharmaceutical companies also have human rights responsibilities in relation to access to medicines. This article provides an introduction to these responsibilities. It briefly outlines the new UN Guiding Principles on Business and Human Rights and places the human rights responsibilities of pharmaceutical companies in this context. The authors draw from the work of the first UN Special Rapporteur on the right to the highest attainable standard of health, in particular the Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines that he presented to the UN General Assembly in 2008, and his UN report on GlaxoSmithKline (GSK). While the Guiding Principles on Business and Human Rights are general human rights standards applicable to all business entities, the Human Rights Guidelines for Pharmaceutical Companies consider the specific human rights responsibilities of one sector (pharmaceutical companies) in relation to one area of activity (access to medicines). The article signals the human rights responsibilities of all pharmaceutical companies, with particular attention to patent-holding pharmaceutical companies. Adopting a right-to-health "lens," the article discusses GSK and accountability. The authors argue that human rights should shape pharmaceutical companies' policies, and provide standards in relation to which pharmaceutical companies could, and should, be held accountable. They conclude that it is now crucial to devise independent, accessible, transparent, and effective mechanisms to monitor pharmaceutical companies and hold them publicly accountable for their human rights responsibilities.
© 2012 American Society of Law, Medicine & Ethics, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789042     DOI: 10.1111/j.1748-720X.2012.00660.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  3 in total

Review 1.  Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms.

Authors:  Hayley Droppert; Sara Bennett
Journal:  Global Health       Date:  2015-04-09       Impact factor: 4.185

2.  Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.

Authors:  Tatiana Dănescu; Maria-Alexandra Popa
Journal:  Global Health       Date:  2020-12-10       Impact factor: 4.185

3.  Multidrug-Resistant TB: Implementing the Right to Health through the Right to Enjoy the Benefits of Scientific Progress.

Authors:  Leslie London; Helen Cox; Fons Coomans
Journal:  Health Hum Rights       Date:  2016-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.